Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

lopinavir/ritonavir (Rx)Brand and Other Names:Kaletra

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

lopinavir/ritonavir

tablet

  • 100mg/25mg
  • 200mg/50mg

oral solution

  • (400mg/100mg)/5mL
more...

HIV-1 Infection

400 mg/100 mg PO q12hr, OR

800 mg/200 mg PO qDay in patients with <3 lopinavir resistance-associated substitutions

Once-daily dosing is only recommended for protease inhibitor-naïve patients and not for pregnant women or coadministration with efavirenz, nevirapine, fosamprenavir, nelfinavir, carbamazepine, phenytoin, or phenobarbital

Coadministration with efavirenz, nevirapine, fosamprenavir, or nelfinavir

  • Protease inhibitor naive or experienced
  • 500 mg/125 mg PO q12hr (ie, 2 x 200 mg/50 mg + 100 mg/25 mg), OR
  • Oral solution or capsules: 533 mg/133 mg PO q12hr (ie, ~6.5 mL q12hr)

Administration

Tablets: Administer with or without food

Oral solution/capsules: Administer with food

Monitor: LFTs

Dosage Forms & Strengths

lopinavir/ritonavir

tablet

  • 100mg/25mg
  • 200mg/50mg

oral solution

  • (400mg/100mg)/5mL
more...

HIV-1 Infection

Do not use once-daily dosing in children or adolescents (administer q12hr)

<2 weeks: Safety and efficacy not established (see cautions)

2 weeks-6 months

  • PO solution: 300 mg/75 mg (LPV/r) per m² or 16 mg/4 mg LPV/r per kg PO q12hr  
  • Do not administer with efavirenz, nevirapine, fosamprenavir, or nelfinavir in infants aged <6 months
  • Use of 300 mg/75 mg (LPV/r) per m² in infants aged <6 months associated with lower LPV trough levels than those found in adults; evaluate LPV dosing and adjusted for growth at frequent intervals

Oral solution: 6 months-18 years (not receiving concomitant efavirenz, nevirapine, fosamprenavir, or nelfinavir)

  • 230 mg/57.5 mg/m² per dose PO q12hr, not to exceed 400 mg/dose of lipinavir, OR weight-based dosing listed below
  • 7 to <15 kg: 12 mg/kg/dose PO q12hr based on lopinavir component
  • 15-40 kg: 10 mg/kg/dose PO q12hr based on lopinavir componen; not to exceed 400 mg/100 mg PO q12hr
  • >40 kg: As adults; 400 mg/100 mg PO q12hr

Oral tablets: 6 months-18 years (not receiving concomitant efavirenz, nevirapine, fosamprenavir, or nelfinavir)

  • 15-20 kg or 0.6 to <0.8 m²: 200 mg/50 mg (2 tab) PO q12hr
  • >20-30 kg or 0.8 to <1.2 m²: 300 mg/75 mg (3 tab) PO q12hr
  • >30-45 kg or 1.2 to <1.7 m²: 400 mg/100 mg PO q12hr
  • >45 kg or >1.7 m²: 400-600 mg/100-150 mg PO q12hr (use higher dose for treatment-experienced patients)

6 months-18 years (coadministered with efavirenz, nevirapine, fosamprenavir, or nelfinavir)

  • 300 mg/75 mg (LPV/r)/m²/dose PO bid, not to exceed 400 mg/dose of lopinavir
  • FDA-approved dose: 500 mg/125 mg LPV/r PO bid, administer as combination of 2 tab of 200/50 mg LPV/r and 1 tab of 100 mg/25 mg LPV/r
  • Most NIH Panel members recommend 600 mg/150 mg LPV/r PO bid

Administration

Do not administer qDay in pediatric patients <18 yr; administer q12hr

Tablets: Administer with or without food

Oral solution: Administer with food

Monitor: LFTs

Next

Interactions

Interaction Checker

lopinavir/ritonavir and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Diarrhea (7-9%)

            Hyperlipidemia (3-39%)

            Nausea (5-16%)

            Rash (12%)

            Abdominal pain (1-11%)

            Nausea (5-16%)

            ALT increased (1-11%)

            1-10% (selected)

            Headache (2-6%)

            Elevated LFTs (2-10%)

            Weakness (< 9%)

            Hyperuricemia (< 5%)

            Flatulence (1-4%)

            Neutropenia (1-5%)

            <1%

            Stevens Johnson Syndrome

            Erythema multiforme

            Toxic epidermal necrolysis

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to ritonavir, lopinavir

            Concomitant CYP3A4 inducers and/or major substrates

            Drugs that are contraindicated with lopinavir/ritonavir include alpha1-adrenoreptor agonists (eg, alfuzosin), antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, quinidine), rifampin, voriconazole, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, St. John’s wort, lovastatin, simvastatin, pimozide, sildenafil (when used for PAH), midazolam, and triazolam

            Cautions

            Risks of: pancreatitis (especially if history); hepatotoxicity (especially if preexisiting liver disease); hyperlipidemia

            Risk of immune reconstitution syndrome if used with HAART

            QT and PR interval prolonation and torsades de pointes have been reported rarely; do not use saquinavir/ritonavir with congenital or documented acquired QT prolongation (>450 msec), refractory hypokalemia or magnesemia, and in combination with drugs that prolong QT interval

            Risks of fat redistribution, hemolytic anemia, hyperglycemia, hyperbilirubinemia if used in combination with other antiretroviral drugs

            Increased bleeding, including spontaneous skin hematomas and hemarthrosis reported in patients with hemophilia type A and B treated with protease inhibitors; A causal relationship between protease inhibitor therapy and these events has not been established

            Adverse effects reported but casual link unclear includes new-onset or worsening of DM and bleeding problems

            Oral solution in newborns

            • Contains alcohol 42.4% and propylene glycol
            • Increased risk for toxicities (ie, serious heart, kidney, or breathing problems) in premature babies or newborns because of decreased ability to eliminate propylene glycol
            • Postmarketing life-threatening cases of cardiac toxicity (including complete AV block, bradycardia, and cardiomyopathy), lactic acidosis, acute renal failure, CNS depression and respiratory complications leading to death have been reported, predominantly in preterm neonates
            • Avoid oral solution in premature babies until PMA 42 weeks (ie, 14 days after their due date), or in full-term babies younger than 14 days of age unless a healthcare professional believes that the benefit of using Kaletra oral solution to treat HIV infection immediately after birth outweighs the potential risks
            • In such cases, FDA strongly recommends monitoring for increases in serum osmolality, serum creatinine, and other signs of toxicity
            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Newborn infants exposed in utero and then as neonates have an increased risk for congenital adrenal hyperplasia characterized by excessive production of 17-hydroxyproesterone (17OHP) and above-normal levels of DHEA-S; Simon A, et al. JAMA 2011;306(1):11

            Lactation: unknown if distributed in breast milk; HIV+ women shouldn't breastfeed anyway

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Protease Inhibitor; inhibits cleavage of Gag-Pol polyprotein precursors, which in turn causes the formation of immature, noninfectious viral particles.

            Main antiretroviral effect due to lopinavir; ritonavir inhibits metabolism to prolong action/increase serum concentration

            Pharmacokinetics

            Lopinavir

            • Peak Plasma Time: 4 hr
            • Peak Plasma Concentration: (800 mg qDay x 4 wk): 11.8±3.7 mcg/mL
            • Half-life: 5-6 hr
            • Protein Bound: 98-99%
            • Metabolism: CYP3A4 which is inhibited by ritonavir
            • Excretion: Feces (83%); urine (10%)

            Ritonavir

            • Absorption: variable, with or without food
            • Vd: 0.16-0.66 L/kg (high concentrations in serum & lymph nodes)
            • Protein Bound: 98-99%
            • Metabolism: Hepatic; five metabolites, low concentration of an active metabolite achieved in plasma (oxidative)
            • Half-life: 3-5 hr
            • Peak plasma time: 2 hr (oral solution)
            • Excretion: Urine (11%); feces (86%)
            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.